Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human phase 1 study of VX-983 with placebo control and midazolam interaction assessment
NL-OMON37286Phase 1Active, not recruiting
- Sponsor
- Vertex Pharmaceuticals
- Start
- Jan 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of VX-983 in cystic fibrosis (CF) (6 arms), sponsored by Vertex Pharmaceuticals. Primary endpoint: Safety and tolerability. Started Jan 2013; status: active, not recruiting.
02
Drugs
VX-983
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on NL-OMON37286.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON37286.